LobbyingContinuus Pharmaceuticals lobbying by quarter
Continuus Pharmaceuticals's latest lobbying report covers Q2 2026, at $10K. The four quarters Q4 2025–Q3 2026 total $130K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Manufacturing.
Continuus Pharmaceuticals
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $130K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $20K | 1 |
| Q1 2023 | $20K | 1 |
| Q2 2023 | $10K | 1 |
| Q3 2023 | $0 | 0 |
| Q4 2023 | $0 | 0 |
| Q1 2024 | $0 | 0 |
| Q2 2024 | $0 | 0 |
| Q3 2024 | $0 | 0 |
| Q4 2024 | $0 | 0 |
| Q1 2025 | $0 | 0 |
| Q2 2025 | $0 | 0 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $60K | 1 |
| Q1 2026 | $60K | 1 |
| Q2 2026 | $10K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$90K · 6 reports
- Manufacturing$65K · 3 reports
- Defense$25K · 3 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES6 reports
- SENATE6 reports
- Health & Human Services, Dept of (HHS)4 reports
- White House Office1 reports
Firms it paid
| Firm | ||
|---|---|---|
| Capitol Counsel | $130K | 3 quarters |
| ML Strategies | $50K | 3 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/16for Q2 | Capitol Counsel | $10K |
| 04/16for Q1 | Capitol Counsel | $60K |
| 01/19for Q4 2025 | Capitol Counsel | $60K |
| 01/16for Q4 2025 | Capitol Counsel | Under $5,000 |
| 23/07/20for Q2 2023 | ML Strategies | $10K |
| 23/04/20for Q1 2023 | ML Strategies | $20K |
| 23/01/20for Q4 2022 | ML Strategies | $20K |